Abstract: The present disclosure provides a composition comprising of Glycyrrhiza glabra extract and Vitex negundo extract that is useful in pain and/or inflammation management. Also provided is a method of monitoring of pain and/or inflammation at site by measuring fluorescence of said composition.
CLIAMS:1. A composition comprising of:
a. Glycyrrhiza glabra extract; and
b. Vitex negundo extract,
wherein said composition inhibits pain.
2. The composition as claimed in claim 1, wherein Glycyrrhiza glabra extract to Vitex negundo extract w/w ratio in said composition is 1:0.2-1:0.8.
3. A composition comprising of:
a. Glycyrrhiza glabra extract; and
b. Vitex negundo extract,
wherein said composition inhibits inflammation.
4. The composition as claimed in claim 3, wherein Glycyrrhiza glabra extract to Vitex negundo extract w/w ratio in said composition is 1:0.2.
5. The composition as claimed in any of the claims 1-4, wherein said composition has auto-fluorescence properties.
6. A method of inhibiting pain, said method comprising of:
a. obtaining a composition as claimed in any of the claims 1-2, or 5, and
b. contacting said composition with site of pain,
wherein said method inhibits pain.
7. A method of inhibiting inflammation, said method comprising of:
a. obtaining a composition as claimed in any of the claims 3-5; and
b. contacting said composition with site of inflammation,
wherein said method inhibits inflammation.
8. An adhesive patch for topical application for management of pain, said adhesive patch comprising of a composition as claimed in any of the claims 1-2, or 5.
9. An adhesive patch for topical application for management of inflammation, said adhesive patch comprising of a composition as claimed in any of the claims 3-5.
10. The adhesive patch as claimed in any of the claims 8-9, further comprising of suitable carriers, diluents, and excipients
11. A method of preparing an adhesive patch as claimed in any of the claims 8-10.
12. A method of monitoring pain management, said method comprising of:
a. obtaining a composition as claimed in any of the claims 1-2, or 5; or an adhesive patch as claimed in any of the claims 8, or 10;
b. contacting said composition or adhesive patch with site of pain; and
c. monitoring fluorescence activity of said composition or adhesive patch,
wherein increase in fluorescence of said composition or adhesive patch is indicative of effective pain management.
13. A method of monitoring inflammation management, said method comprising of:
a. obtaining a composition as claimed in any of the claims 3-5; or an adhesive patch as claimed in any of the claims 9-10;
b. contacting said composition or adhesive patch with site of inflammation; and
c. monitoring fluorescence activity of said composition or adhesive patch,
wherein increase in fluorescence of said composition or adhesive patch is indicative of effective inflammation management.
14. A composition as claimed in any of the claims 1-2, or 5; or an adhesive patch as claimed in any of the claims 8, or 10 for use in pain management.
15. A composition as claimed in any of the claims 3-5; or an adhesive patch as claimed in any of the claims 9-10 for use in inflammation management.
,TagSPECI:As Attached
| Section | Controller | Decision Date |
|---|---|---|
| # | Name | Date |
|---|---|---|
| 1 | 1475-CHE-2015-IntimationOfGrant26-09-2023.pdf | 2023-09-26 |
| 1 | PD015621IN-SC SPEC FOR FILING.pdf | 2015-03-28 |
| 2 | 1475-CHE-2015-PatentCertificate26-09-2023.pdf | 2023-09-26 |
| 2 | PD015621IN-SC FORM 5.pdf | 2015-03-28 |
| 3 | PD015621IN-SC FORM 3.pdf | 2015-03-28 |
| 3 | 1475-CHE-2015-Written submissions and relevant documents [05-12-2022(online)].pdf | 2022-12-05 |
| 4 | PD015621IN-SC FIGURES FOR FILING.pdf | 2015-03-28 |
| 4 | 1475-CHE-2015-Correspondence to notify the Controller [18-11-2022(online)].pdf | 2022-11-18 |
| 5 | 1475-CHE-2015-US(14)-ExtendedHearingNotice-(HearingDate-21-11-2022).pdf | 2022-10-28 |
| 5 | 1475-CHE-2015 POWER OF ATTORNEY 24-04-2015.pdf | 2015-04-24 |
| 6 | 1475-CHE-2015-Correspondence to notify the Controller [06-09-2022(online)].pdf | 2022-09-06 |
| 6 | 1475-CHE-2015 FORM-1 24-04-2015.pdf | 2015-04-24 |
| 7 | 1475-CHE-2015-Correspondence to notify the Controller [31-08-2022(online)].pdf | 2022-08-31 |
| 7 | 1475-CHE-2015 CORRESPONDENCE OTHERS 24-04-2015.pdf | 2015-04-24 |
| 8 | 1475-CHE-2015-US(14)-HearingNotice-(HearingDate-02-09-2022).pdf | 2022-08-01 |
| 8 | 1475-CHE-2015-FORM 18 [01-02-2019(online)].pdf | 2019-02-01 |
| 9 | 1475-CHE-2015-CLAIMS [19-11-2021(online)].pdf | 2021-11-19 |
| 9 | 1475-CHE-2015-FER.pdf | 2021-10-17 |
| 10 | 1475-CHE-2015-FER_SER_REPLY [19-11-2021(online)].pdf | 2021-11-19 |
| 11 | 1475-CHE-2015-CLAIMS [19-11-2021(online)].pdf | 2021-11-19 |
| 11 | 1475-CHE-2015-FER.pdf | 2021-10-17 |
| 12 | 1475-CHE-2015-FORM 18 [01-02-2019(online)].pdf | 2019-02-01 |
| 12 | 1475-CHE-2015-US(14)-HearingNotice-(HearingDate-02-09-2022).pdf | 2022-08-01 |
| 13 | 1475-CHE-2015 CORRESPONDENCE OTHERS 24-04-2015.pdf | 2015-04-24 |
| 13 | 1475-CHE-2015-Correspondence to notify the Controller [31-08-2022(online)].pdf | 2022-08-31 |
| 14 | 1475-CHE-2015 FORM-1 24-04-2015.pdf | 2015-04-24 |
| 14 | 1475-CHE-2015-Correspondence to notify the Controller [06-09-2022(online)].pdf | 2022-09-06 |
| 15 | 1475-CHE-2015 POWER OF ATTORNEY 24-04-2015.pdf | 2015-04-24 |
| 15 | 1475-CHE-2015-US(14)-ExtendedHearingNotice-(HearingDate-21-11-2022).pdf | 2022-10-28 |
| 16 | 1475-CHE-2015-Correspondence to notify the Controller [18-11-2022(online)].pdf | 2022-11-18 |
| 16 | PD015621IN-SC FIGURES FOR FILING.pdf | 2015-03-28 |
| 17 | 1475-CHE-2015-Written submissions and relevant documents [05-12-2022(online)].pdf | 2022-12-05 |
| 17 | PD015621IN-SC FORM 3.pdf | 2015-03-28 |
| 18 | 1475-CHE-2015-PatentCertificate26-09-2023.pdf | 2023-09-26 |
| 18 | PD015621IN-SC FORM 5.pdf | 2015-03-28 |
| 19 | PD015621IN-SC SPEC FOR FILING.pdf | 2015-03-28 |
| 19 | 1475-CHE-2015-IntimationOfGrant26-09-2023.pdf | 2023-09-26 |
| 1 | 2021-05-0712-50-23E_07-05-2021.pdf |